MCID: BRN012
MIFTS: 56

Bronchiolitis Obliterans

Categories: Rare diseases, Respiratory diseases

Aliases & Classifications for Bronchiolitis Obliterans

MalaCards integrated aliases for Bronchiolitis Obliterans:

Name: Bronchiolitis Obliterans 12 52 54 43 15 37 17 71
Obliterative Bronchiolitis 12 52 36
Bronchiolitis Fibrosa Obliterans 12 71
Bronchiolitis, Exudative 71
Bronchiolitis Exudativa 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2799
KEGG 36 H01873
MeSH 43 D001989
NCIt 49 C62580
SNOMED-CT 67 31886003 40100001
UMLS 71 C0006272 C2350876 C3241980

Summaries for Bronchiolitis Obliterans

KEGG : 36 Obliterative bronchiolitis (OB), also known as bronchiolitis obliterans, is a rare but serious condition resulting in progressive and irreversible airway obstruction. This disease is the result of injury to the respiratory and terminal bronchioles from a wide variety of potential causes. Although the pathogenesis of OB remains poorly understood, it seems clear that a multifaceted process of inflammation and resultant fibrotic transition occurs, resulting in airflow limitation and development of disease. Although OB has been described in all age groups, the frequency of underlying causes and potential prognoses are different for children and adults. For example, OB in children is most often seen following a severe lower-respiratory-tract infection, usually of adenovirus, whereas OB in adults is more commonly associated with occupational inhalation injuries, hypersensitivity pneumonitis, and autoimmune disorders. In lung transplant recipients, bronchiolitis obliterans syndrome is the major cause of death after the first year of transplantation and is a form of allograft rejection. There is no uniformly accepted treatment protocol for patients with OB. Many patients are tried on corticosteroids or other immunosuppressants based on anecdotal evidence of improvement. However, these medications have significant toxicity.

MalaCards based summary : Bronchiolitis Obliterans, also known as obliterative bronchiolitis, is related to cryptogenic organizing pneumonia and chronic graft versus host disease. An important gene associated with Bronchiolitis Obliterans is CXCL8 (C-X-C Motif Chemokine Ligand 8), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Mechlorethamine and Erythromycin have been mentioned in the context of this disorder. Affiliated tissues include Lung, heart and bone, and related phenotypes are immune system and homeostasis/metabolism

Disease Ontology : 12 A obstructive lung disease involving obstruction of the bronchioles due to inflammation and fibrosis which occurs as a complication of various lung conditions or physiological insults.

NIH Rare Diseases : 52 Bronchiolitis obliterans is an inflammatory condition that affects the lung's tiniest airways, the bronchioles. In affected people, the bronchioles may become damaged and inflamed leading to extensive scarring that blocks the airways. Signs and symptoms of the condition include a dry cough; shortness of breath; and/or fatigue and wheezing in the absence of a cold or asthma. Many different chemicals (such as nitrogen oxides, ammonia, welding fumes or food flavoring fumes) and respiratory infections can cause lung injury that leads to bronchiolitis obliterans. It can also be associated with rheumatoid arthritis and graft-versus-host disease following a lung or hematopoietic cell transplantation . While there is no way to reverse the disease, treatments are available that may stabilize or slow the progression. Another similarly named disease, bronchiolitis obliterans organizing pneumonia , is a completely different disease.

Wikipedia : 74 Obliterative bronchiolitis (OB), also known as constrictive bronchiolitis and popcorn lung, is a disease... more...

Related Diseases for Bronchiolitis Obliterans

Diseases related to Bronchiolitis Obliterans via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 780)
# Related Disease Score Top Affiliating Genes
1 cryptogenic organizing pneumonia 34.1 TNF TIMP1 SFTPD MMP9 CXCL8 CRP
2 chronic graft versus host disease 32.0 IL10 IFNG
3 graft-versus-host disease 31.9 TNF IL6 IL10 IFNG
4 cytomegalovirus infection 31.4 TNF IL6 CXCL8
5 acute graft versus host disease 31.4 TNF IL10 IFNG
6 idiopathic interstitial pneumonia 31.3 SFTPD IL13 IFNG CXCL8
7 bronchiolitis 31.3 TNF SFTPD SCGB1A1 IL6 IL17A IL13
8 bronchiectasis 31.3 TNF MPO MMP8 IL6 CXCL8 CRP
9 erythema multiforme 31.2 TNF IL6 IFNG CXCR3 CXCL8
10 eosinophilic pneumonia 31.2 SFTPD IL13 CXCL8
11 pemphigus 31.1 TNF PPL IL10 EVPL
12 neurofibromatosis, type ii 31.0 TNF IL6 CXCL8
13 gastroesophageal reflux 30.9 TNF MPO IL6 FOXP3 CXCL8
14 rheumatoid arthritis interstitial lung disease 30.9 TNF SFTPD CRP
15 vasculitis 30.8 TNF MPO IL6 IL17A CRP
16 exanthem 30.8 TNF IL6 IL10 CXCL8 CRP
17 pustulosis of palm and sole 30.8 TNF IL17A CXCL8
18 crohn's colitis 30.7 TNF IFNG CXCL8
19 mixed connective tissue disease 30.7 TNF IL6 IL10 IFNG
20 invasive aspergillosis 30.7 SFTPD IL10 IFNG CXCL8
21 cold agglutinin disease 30.7 IL6 CRP
22 post-transplant lymphoproliferative disease 30.7 TNF IL6 IL10
23 ige responsiveness, atopic 30.7 IL13 IL10 IFNG
24 aspergillosis 30.7 TNF SFTPD IL6 IL10 IFNG CXCL8
25 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.7 IL17A IL10 IFNG FOXP3
26 miliary tuberculosis 30.7 TNF IFNG CRP
27 stevens-johnson syndrome/toxic epidermal necrolysis 30.7 IL13 IFNG CXCR3
28 pulmonary hypertension 30.6 TNF TIMP1 IL6 CXCL8 CRP BMP6
29 allergic bronchopulmonary aspergillosis 30.6 SFTPD IL10 IFNG
30 subacute thyroiditis 30.6 TNF IL6 CRP
31 extrinsic allergic alveolitis 30.6 SFTPD MPO IL6 IL10 CXCR3 CXCL8
32 alpha-1-antitrypsin deficiency 30.6 TNF MPO CXCL8
33 thyroiditis 30.6 TNF IL6 IL10 FOXP3
34 granulomatosis with polyangiitis 30.6 TNF MPO IL17A CRP
35 acquired immunodeficiency syndrome 30.6 TNF IL6 IL10 IFNG CRP
36 cystic fibrosis 30.5 TNF SFTPD MPO IL6 IL17A IL10
37 neutrophilia, hereditary 30.5 MPO IL6 CRP
38 duodenal ulcer 30.5 TNF IL6 IL10 CXCL8
39 bronchopneumonia 30.5 TNF MPO IL6 IL10 CXCL8 CRP
40 plasmodium vivax malaria 30.5 TNF IL6 IL10 IFNG
41 pulmonary emphysema 30.5 TIMP1 SFTPD MMP9 MMP8 CXCL8
42 melioidosis 30.5 TNF IL6 IL10 IFNG
43 arthropathy 30.5 TNF IL6 IFNG CRP
44 cryptococcosis 30.5 TNF IL17A IL13 IL10 IFNG
45 adult-onset still's disease 30.5 TNF IL6 CXCL8 CRP
46 localized scleroderma 30.5 TNF IL6 IL13 BMP6
47 pertussis 30.5 TNF IL6 IL10 CXCL8
48 polyarteritis nodosa 30.5 MPO IL6 CRP
49 systemic scleroderma 30.4 TNF SFTPD IL6 IL17A IFNG CRP
50 cryoglobulinemia 30.4 TNF IL6 IL10 IFNG CXCR3

Graphical network of the top 20 diseases related to Bronchiolitis Obliterans:



Diseases related to Bronchiolitis Obliterans

Symptoms & Phenotypes for Bronchiolitis Obliterans

MGI Mouse Phenotypes related to Bronchiolitis Obliterans:

45 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 10.39 CRP CXCR3 FOXP3 IFNG IL10 IL13
2 homeostasis/metabolism MP:0005376 10.38 CRP CXCR3 FOXP3 IFNG IL10 IL13
3 hematopoietic system MP:0005397 10.34 CXCR3 FOXP3 IFNG IL10 IL13 IL17A
4 growth/size/body region MP:0005378 10.32 BMP6 FOXP3 IFNG IL10 IL13 IL17A
5 cardiovascular system MP:0005385 10.28 CRP CXCR3 FOXP3 IFNG IL10 IL6
6 mortality/aging MP:0010768 10.25 CXCR3 FOXP3 IFNG IL10 IL13 IL17A
7 integument MP:0010771 10.17 EVPL FOXP3 IFNG IL10 IL13 IL17A
8 digestive/alimentary MP:0005381 10.13 FOXP3 IFNG IL10 IL13 IL17A IL6
9 muscle MP:0005369 9.97 IFNG IL10 IL13 IL6 MMP9 MPO
10 neoplasm MP:0002006 9.97 CXCR3 IFNG IL10 IL6 MMP8 MMP9
11 renal/urinary system MP:0005367 9.81 CXCR3 FOXP3 IFNG IL17A IL6 MMP9
12 no phenotypic analysis MP:0003012 9.8 FOXP3 IFNG IL10 IL13 IL17A PDGFB
13 reproductive system MP:0005389 9.65 BMP6 FOXP3 IFNG IL10 IL13 IL6
14 respiratory system MP:0005388 9.44 CXCR3 FOXP3 IFNG IL10 IL13 IL17A

Drugs & Therapeutics for Bronchiolitis Obliterans

Drugs for Bronchiolitis Obliterans (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 132)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mechlorethamine Approved, Investigational Phase 4 51-75-2 4033
2
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560 441411
3
Aztreonam Approved Phase 4 78110-38-0 5362041 5742832
4
Sotalol Approved Phase 4 959-24-0, 3930-20-9 5253
5
Macitentan Approved Phase 4 441798-33-0
6
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
7
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
8
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
9 Cysteinyl-leukotriene Phase 4
10 Tiotropium Bromide Phase 4 136310-93-5
11 Adrenergic Agonists Phase 4
12 Adrenergic beta-Agonists Phase 4
13 Albuterol Phase 4
14 Tocolytic Agents Phase 4
15 Cholinergic Agents Phase 4
16 Bromides Phase 4
17 Parasympatholytics Phase 4
18 Cholinergic Antagonists Phase 4
19 Gastrointestinal Agents Phase 4
20 Erythromycin Ethylsuccinate Phase 4
21 Erythromycin Estolate Phase 4
22 Erythromycin stearate Phase 4
23 Trace Elements Phase 4
24 Micronutrients Phase 4
25 Nutrients Phase 4
26 Vitamin D2 Phase 4
27 Ergocalciferols Phase 4
28 Olive Phase 4
29 Vitamins Phase 4
30 Calciferol Phase 4
31 Calcium, Dietary Phase 4
32 lysine Phase 4
33 Vaccines Phase 4
34 Neurotransmitter Agents Phase 4
35 Autonomic Agents Phase 4
36 Adrenergic Agents Phase 4
37 Anti-Arrhythmia Agents Phase 4
38 Adrenergic Antagonists Phase 4
39 Adrenergic beta-Antagonists Phase 4
40 Sodium Channel Blockers Phase 4
41 Diuretics, Potassium Sparing Phase 4
42 Sympatholytics Phase 4
43 Endothelin A Receptor Antagonists Phase 4
44 Endothelin Receptor Antagonists Phase 4
45
Clarithromycin Approved Phase 3 81103-11-9 84029
46
Basiliximab Approved, Investigational Phase 3 179045-86-4, 152923-56-3
47
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
48
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
49
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
50
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0

Interventional clinical trials:

(show top 50) (show all 120)
# Name Status NCT ID Phase Drugs
1 A Randomized, Double Blind, Placebo Controlled Trial With Montelukast to Treat Bronchiolitis Obliterans Syndrome After Lung Transplantation Completed NCT01211509 Phase 4 Montelukast
2 Acute Bronchodilator Responsiveness in Obliterative Bronchiolitis (OB) Following Hematopoietic Stem Cell Transplantation Completed NCT01112241 Phase 4 albuterol plus tiotropium
3 Low-Dose Long-Term Prescription of Erythromycin in Mustard-Induced Bronchiolitis Obliterans Completed NCT00367419 Phase 4 Erythromycin
4 A Randomized Double Blind Placebo Controlled Trial With Vitamin D to Prevent Bronchiolitis Obliterans Syndrome After Lung Transplantation Completed NCT01212406 Phase 4 Vitamin D
5 Randomized Double-blind Placebo-controlled Prevention Trial of Azithromycin in Lung Transplantation. Completed NCT01009619 Phase 4 Azithromycin;Placebo
6 Aztreonam Lysine for Inhalation (AZLI) in the Treatment of Early Bronchiolitis Obliterans Syndrome (BOS) After Lung Transplantation Completed NCT01469364 Phase 4 Aztreonam Lysine for Inhalation (AZLI)
7 Improving the Humoral Response to Influenza Vaccine in Lung Transplant Recipients by an Intradermal Strategy Completed NCT00402805 Phase 4
8 A Prospective, Open-label Study of Azithromycin for Lymphocytic Bronchiolitis/Bronchitis After Lung Transplantation Completed NCT01109160 Phase 4 Azithromycin Dihydrate
9 A Pilot and Feasibility Study to Determine if a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs Recruiting NCT02347111 Phase 4 Flecainide;Sotalol
10 Potential Therapy With MACITENTAN in the Treatment of Chronic Lung Allograft Dysfunction (CLAD) After Lung Transplantation Not yet recruiting NCT02893176 Phase 4 macitentan;placebo (for macitentan)
11 Randomized, Open-label, Multi-Center Study Comparing Tacrolimus With Cyclosporin, Both Arms in Combination With Mycophenolate Mofetil and Corticosteroids for Prevention of Bronchiolitis Obliterans Syndrome in Lung Transplant Patients Completed NCT01429844 Phase 3 Tacrolimus;Cyclosporine
12 Phase III, Randomized, Double Blind Study of Low Dose Long Term Clarithromycin Versus Placebo in Treatment of Chronic Pulmonary Lesions Due to Sulfur Mustard Completed NCT00381147 Phase 3 Clarithromycin
13 A Multi-Center, Randomized, Controlled Study to Demonstrate the Efficacy and Safety of Cyclosporine Inhalation Solution (CIS) in Improving Bronchiolitis Obliterans Syndrome-Free Survival Following Lung Transplantation Completed NCT00755781 Phase 3 Cyclosporine Inhalation Solution (CIS)
14 A Randomized, Double Blind, Placebo Controlled Study Comparing Simulect Plus Standard Immunosuppression to Standard Immunosuppression Alone for the Prevention of Acute Rejection and Bronchiolitis Obliterans Syndrome in Bilateral Lung and Single Lung Transplant Patients Completed NCT00188825 Phase 3 basiliximab
15 Immunosuppressive Therapy With Certican (Everolimus) After Lung Transplantation Completed NCT00402532 Phase 3 Everolimus;Mycophenolatmofetil
16 Bronchopulmonary Function in Response to Azithromycin Treatment for Chronic Lung Disease in HIV-infected Children Completed NCT02426112 Phase 3 Azithromycin;Placebo
17 A Randomized Double-Blind, Placebo-Controlled Trial of Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Cell Transplantation (BMT CTN #0403) Completed NCT00421174 Phase 3 Etanercept;Placebo plus corticosteroid
18 A Multi-center, Randomised, Double-blind Trial of Nintedanib in Lung Transplant (LTx) Recipients With Bronchiolitis Obliterans Syndrome (BOS) Grade 1-2 Recruiting NCT03283007 Phase 3 Nintedanib;Placebo
19 Extracorporeal Photopheresis for the Management of Progressive Bronchiolitis Obliterans Syndrome in Medicare-Eligible Recipients of Lung Allografts Recruiting NCT02181257 Phase 3
20 A Phase III, Prospective, Multicenter, Randomized, Controlled Clinical Trial to Demonstrate the Effectiveness and Safety of Liposomal Cyclosporine A (L-CsA) Inhalation Solution Delivered Via the PARI Investigational eFlow® Device Plus Standard of Care Versus Standard of Care Alone in the Treatment of Bronchiolitis Obliterans Syndrome in Patients Post Single Lung Transplantation Recruiting NCT03657342 Phase 3 Liposomal Cyclosporine A
21 A Phase III, Prospective, Multicenter, Randomized, Controlled Clinical Trial to Demonstrate the Effectiveness and Safety of Liposomal Cyclosporine A (L-CsA) Inhalation Solution Delivered Via the PARI Investigational eFlow® Device Plus Standard of Care Versus Standard of Care Alone in the Treatment of Bronchiolitis Obliterans Syndrome in Patients Post Double Lung Transplantation Recruiting NCT03656926 Phase 3 Liposomal Cyclosporine A
22 Evaluation of the Efficacy of Azithromycin to Prevent Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation Active, not recruiting NCT01959100 Phase 3 Azithromycin;Placebo
23 A European Multi-center, Randomised, Double-blind Trial of Pirfenidone in Bronchiolitis-obliterans-syndrome Grade 1-3 in Lung Transplant Recipients Active, not recruiting NCT02262299 Phase 2, Phase 3 Pirfenidone;Placebo
24 A Phase III, Multicenter Open-Label, Extension Clinical Trial to Demonstrate the Effectiveness and Safety of Liposomal Cyclosprine A (L-CsA) Inhalation Solution Delivered Via the PARI Investigational eFlow® Device Plus Standard of Care in the Treatment of Bronchiolitis Obliterans Syndrome in Patients Post Single or Double Lung Transplantation Not yet recruiting NCT04039347 Phase 3 Liposomal Cyclosporine A 5 mg;Liposomal Cyclosporine A 10 mg
25 A Long-term Safety Follow-up Study of L-CsA Therapy for Patients Who Participated in Study 12011.201 and Volunteered to Continue or to Cross-over to L-CsA Inhalation Therapy Terminated NCT01439958 Phase 3 Inhalation
26 CIS002: An Open-Label, Multi-Center, Extension Study of Cyclosporine Inhalation Solution in Subjects Previously Enrolled in the APT Study CIS001 Terminated NCT00938236 Phase 3 Cyclosporine Inhalation Solution (CIS)
27 A Phase II, Multicentre, Randomised, Double-blind, Placebo Controlled Clinical Trial to Investigate the Efficacy and Safety of Aerosolised Liposomal Ciclosporin A Versus Aerosolised Placebo in the Prevention of Bronchiolitis Obliterans Syndrome in Lung Transplant Patients Terminated NCT01334892 Phase 2, Phase 3 Cyclosporine Inhalation Solution
28 Prospective Randomized Trial to Compare a Twice Daily to a Once Daily Administration of the Tacrolimus in Lung Transplanted Patients Terminated NCT00930241 Phase 3 Advagraf®;Prograf®
29 Eine Phase II Studie über Interferon Gamma 1b Zur Behandlung Der steroidrefraktären Bronchiolitis Obliterans Nach Allogener SZT Unknown status NCT01639261 Phase 2 Interferon gamma 1b
30 Mesenchymal Stem Cell for Treatment of Interstitial Lung Disease After Allogenetic Hematopoietic Stem Cell Transplantation Unknown status NCT02543073 Phase 1, Phase 2 AZM;Glucocorticoid
31 Open-Labelled, Multicenter Phase II Study of Rituximab in Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease Unknown status NCT00472225 Phase 2 Rituximab
32 Open-labeled Trial to Evaluate the Therapeutic Effects of Inhaled BUDESONIDE/FORMOTEROL in Bronchiolitis Obliterans After Allogeneic Stem Cell Transplantation Completed NCT01560689 Phase 2 Budesonide/formoterol;Placebo
33 Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant Completed NCT01307462 Phase 2 fluticasone propionate;montelukast sodium;azithromycin
34 A Pilot Study to Demonstrate Efficacy and Safety of Aerosol Liposomal Cyclosporine (L-CsA) in the Treatment of Bronchiolitis Obliterans Syndrome After Lung Transplantation Completed NCT01650545 Phase 1, Phase 2 Liposomal aerosol cyclosporine
35 Multi-Institutional Prospective Phase II Study of Montelukast for the Treatment of Bronchiolitis Obliterans Following Allogeneic or Autologous Stem Cell Transplantation in Children and Adults Completed NCT00656058 Phase 2 Singulair (Montelukast Sodium)
36 Phase II Trial of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for Treatment of Bronchiolitis Obliterans Completed NCT01287078 Phase 2 Cyclosporine Inhalation Solution
37 recipientsProspective Evaluation of the Efficacy of Budesonide/Formoterol (Symbicort®) in Bronchiolitis Obliterans in Allogeneic Haematopoietic Stem Cell Transplantation (AHSCT) Recipients Completed NCT00624754 Phase 2 Formoterol/Budesonide;lactose
38 Extension Study (Extended Access) of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans Completed NCT01273207 Phase 2 Cyclosporine Inhalation Solution (CIS)
39 Aerosol Cyclosporine for Prevention of Lung Rejection Completed NCT00268515 Phase 2 cyclosporine;tacrolimus;prednisone;azathioprine
40 Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Acute Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation Completed NCT00029328 Phase 1, Phase 2 etanercept
41 Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Sub-Acute Pulmonary Dysfunction Following Allogeneic Stem Cell Transplantation. A Phase II Study Completed NCT00141726 Phase 2 Etanercept
42 Investigating the Role of Nebulised Mucolytic Therapy During Lower Respiratory Tract Infections Post Lung Transplantation. Completed NCT01952470 Phase 2 Dornase Alfa;Isotonic Saline.
43 An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation Recruiting NCT03978637 Phase 1, Phase 2 Itacitinib
44 Nintedanib Plus Usual Transplant Care Compared to Usual Transplant Care Alone After Single Lung Transplantation in Patients With Idiopathic Pulmonary Fibrosis: a Pilot Randomized Controlled Trial Recruiting NCT03562416 Phase 2 Nintedanib;Placebo Oral Tablet
45 Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell Transplantation (HSCT)- a Multicentre Phase II Trial Recruiting NCT03805477 Phase 2 Nintedanib
46 A Phase II Study of Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT) Recruiting NCT03674047 Phase 2 ruxolitinib
47 A Phase 1b/2 Study of Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation Recruiting NCT02669251 Phase 1, Phase 2 MPH966
48 A Phase 2 Proposal to Test the Efficacy and Tolerability of Bortezomib in Pulmonary Chronic GVHD Active, not recruiting NCT01163786 Phase 2 Bortezomib
49 A Randomized Placebo Controlled Trial of Inhaled Beclomethasone After Community-acquired Respiratory Viral Infection in Lung Transplant Recipients Active, not recruiting NCT02351180 Phase 1, Phase 2 Inhaled beclomethasone;Placebo
50 Treatment of Newly Diagnosed Moderate or Severe Chronic Graft-versus-host Disease With Prednisone and Everolimus (PredEver First) - A Prospective Multicenter Phase IIA Study - Active, not recruiting NCT01862965 Phase 2 PredEver

Search NIH Clinical Center for Bronchiolitis Obliterans

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Bronchiolitis Obliterans cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Bronchiolitis Obliterans:
Mesenchymal stem cells for obliterative bronchiolitis
Embryonic/Adult Cultured Cells Related to Bronchiolitis Obliterans:
Bone marrow-derived mesenchymal stem cells (family)

Cochrane evidence based reviews: bronchiolitis obliterans

Genetic Tests for Bronchiolitis Obliterans

Anatomical Context for Bronchiolitis Obliterans

MalaCards organs/tissues related to Bronchiolitis Obliterans:

40
Lung, Heart, Bone, Bone Marrow, T Cells, Breast, B Cells
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Bronchiolitis Obliterans:
# Tissue Anatomical CompartmentCell Relevance
1 Lung Respiratory Bronchioles Cilliated Cells Affected by disease, potential therapeutic candidate

Publications for Bronchiolitis Obliterans

Articles related to Bronchiolitis Obliterans:

(show top 50) (show all 4204)
# Title Authors PMID Year
1
Editorial: leukocyte trafficking and matrix metalloproteinase-8 in obliterative bronchiolitis. 54 61
20047888 2010
2
Circulating and intrapulmonary C-reactive protein: a predictor of bronchiolitis obliterans syndrome and pulmonary allograft outcome. 54 61
19632576 2009
3
Interleukin-17 and airway inflammation: a longitudinal airway biopsy study after lung transplantation. 54 61
17613395 2007
4
Bronchoalveolar cellularity and interleukin-8 levels in measles bronchiolitis obliterans. 54 61
17494793 2007
5
Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. 54 61
16741151 2006
6
CXCR3 and its ligands in a murine model of obliterative bronchiolitis: regulation and function. 54 61
16709871 2006
7
Comparison of induced sputum and bronchoalveolar lavage in lung transplant recipients. 54 61
16678030 2006
8
Decreased serum levels of clara cell secretory protein (CC16) are associated with bronchiolitis obliterans and may permit early diagnosis in patients after allogeneic stem-cell transplantation. 54 61
15912112 2005
9
Heme oxygenase-1 expression in alveolar macrophages is elevated in patients with bronchiolitis obliterans syndrome after lung transplantation. 54 61
15477118 2004
10
Bronchoalveolar lavage cytokine profile in a cohort of lung transplant recipients: a predictive role of interleukin-12 with respect to onset of bronchiolitis obliterans syndrome. 54 61
15454171 2004
11
Heme-oxygenase-1 expression correlates with severity of acute cellular rejection in lung transplantation. 54 61
15194077 2004
12
Bronchoalveolar lavage fluid characteristics in acute and chronic lung transplant rejection. 54 61
15135367 2004
13
Interleukin-17 stimulates release of interleukin-8 by human airway smooth muscle cells in vitro: a potential role for interleukin-17 and airway smooth muscle cells in bronchiolitis obliterans syndrome. 54 61
14585390 2003
14
Graft protective effects of heme oxygenase 1 in mouse tracheal transplant-related obliterative bronchiolitis. 54 61
12973103 2003
15
Increased expression of heme oxygenase-1 in human lung transplantation. 54 61
12398878 2002
16
Decreased serum and bronchoalveolar lavage levels of Clara cell secretory protein (CC16) is associated with bronchiolitis obliterans syndrome and airway neutrophilia in lung transplant recipients. 54 61
11981419 2002
17
The role of neutrophils in the pathogenesis of obliterative bronchiolitis after lung transplantation. 54 61
11493399 2001
18
Cxcr3 and its ligand CXCL10 are expressed by inflammatory cells infiltrating lung allografts and mediate chemotaxis of T cells at sites of rejection. 54 61
11337368 2001
19
Eosinophilic granulocytes and interleukin-6 level in bronchoalveolar lavage fluid are associated with the development of obliterative bronchiolitis after lung transplantation. 54 61
11112142 2000
20
Clotrimazole inhibits lung fibroblast proliferation in vitro: implications for use in the prevention and treatment of obliterative bronchiolitis after lung transplantation. 54 61
11063355 2000
21
Elevated levels of interleukin-8 and transforming growth factor-beta in bronchoalveolar lavage fluid from patients with bronchiolitis obliterans syndrome: proinflammatory role of bronchial epithelial cells. Munich Lung Transplant Group. 54 61
10933164 2000
22
On interleukin-8, neutrophil activation, and bronchiolitis obliterans syndrome in lung transplantation. 54 61
10933146 2000
23
Cyclosporine, FK506, mycophenolate mofetil, and prednisolone differentially modulate cytokine gene expression in human airway-derived epithelial cells. 54 61
10798763 2000
24
Transforming growth factor beta (TGF-beta) and obliterative bronchiolitis following pulmonary transplantation. 54 61
10528744 1999
25
Bronchoalveolar lavage neutrophilia is associated with obliterative bronchiolitis after lung transplantation: role of IL-8. 54 61
8892657 1996
26
The role of cytokines in human lung fibrosis. 54 61
8680382 1996
27
Small Airway Disease: A Step Closer to Etiology-Based Classification of Bronchiolitis. 61
32005432 2020
28
Azithromycin Use and Increased Cancer Risk among Patients with Bronchiolitis Obliterans after Hematopoietic Cell Transplantation. 61
31682980 2020
29
Total lymphoid irradiation in progressive bronchiolitis obliterans syndrome after lung transplantation: a single-center experience and review of literature. 61
31643104 2020
30
Respiratory sequelae and quality of life in children one-year after being admitted with a lower respiratory tract infection: A prospective cohort study from a developing country. 61
31846223 2020
31
Use of CT-SCAN score and volume measures to early identify restrictive allograft syndrome in single lung transplant recipients. 61
31836403 2020
32
Hydrogen water alleviates obliterative airway disease in mice. 61
31468277 2020
33
Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. 61
32004485 2020
34
Multicenter Evaluation of Parametric Response Mapping as an Indicator of Bronchiolitis Obliterans Syndrome After Hematopoietic Stem Cell Transplantation. 61
32034974 2020
35
Successful bilateral lung transplantation and simultaneous Nuss technique correction of pectus excavatum post-allogeneic haematopoietic stem cell transplantation. 61
31596480 2020
36
[Pulmonary complications in cocaine users]. 61
31883817 2020
37
Etiologic spectrum of interstitial lung diseases in Chinese children older than 2 years of age. 61
31969166 2020
38
Horner's syndrome following single lung transplantation. 61
31778550 2020
39
Imatinib melylate as second-line treatment of bronchiolitis obliterans after allogenic hematopoietic stem cell transplantation in children. 61
31951682 2020
40
Clinical profile and course of children with postinfectious bronchiolitis obliterans from a tertiary care hospital. 61
31898614 2020
41
Outcome after heart-lung or lung transplantation in patients with Eisenmenger syndrome. 61
31434713 2020
42
Azithromycin Partially Mitigates Dysregulated Repair of Lung Allograft Small Airway Epithelium. 61
31985728 2020
43
Need for tracheostomy after lung transplant predicts decreased mid- and long-term survival. 61
31815320 2020
44
Identification and characterization of chronic lung allograft dysfunction patients with mixed phenotype: A single-center study. 61
31958356 2020
45
Use of serum KL-6 level for detecting patients with restrictive allograft syndrome after lung transplantation. 61
31929536 2020
46
LPS-induced airway-centered inflammation leading to BOS-like airway remodeling distinct from RAS-like fibrosis in rat lung transplantation. 61
31929420 2020
47
Ruxolitinib salvage therapy is effective for steroid-refractory graft-versus-host disease in children: A single-center experience. 61
31981413 2020
48
Improvement of native pulmonary alveolar proteinosis after contralateral single living-donor lobar lung transplantation: A case report. 61
31985141 2020
49
Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease. 61
31697815 2020
50
Autoantibodies in lung transplantation. 61
31393646 2020

Variations for Bronchiolitis Obliterans

Expression for Bronchiolitis Obliterans

Search GEO for disease gene expression data for Bronchiolitis Obliterans.

Pathways for Bronchiolitis Obliterans

Pathways related to Bronchiolitis Obliterans according to GeneCards Suite gene sharing:

(show top 50) (show all 64)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.08 TNF TIMP1 PPL PDGFB MPO MMP9
2
Show member pathways
13.88 TNF TIMP1 PDGFB IL6 IL17A IL13
3
Show member pathways
13.74 TNF TIMP1 IL6 IL17A IL13 IL10
4
Show member pathways
13.6 TNF TIMP1 PDGFB IL6 IL17A IL13
5
Show member pathways
13.45 TNF TIMP1 PDGFB IL6 IL17A IL13
6
Show member pathways
13.39 TNF TIMP1 PDGFB MMP9 IL6 IL17A
7
Show member pathways
13.32 TNF TIMP1 PDGFB IL6 IL17A IL13
8
Show member pathways
13.18 TNF SFTPD MMP9 IL6 IL10 IFNG
9 12.9 PDGFB MMP9 IL6 IL13 IFNG CXCL8
10
Show member pathways
12.89 TNF IL6 IL17A IL13 IL10 IFNG
11
Show member pathways
12.75 TNF TIMP1 PDGFB IL6 BMP6
12
Show member pathways
12.65 TNF IL6 IL17A IL10 IFNG
13
Show member pathways
12.65 TNF IL6 IL17A IL13 IL10 IFNG
14 12.64 TNF MPO IL17A IL10 IFNG FOXP3
15
Show member pathways
12.59 TNF TIMP1 PDGFB MPO IL6 IL17A
16
Show member pathways
12.42 PDGFB IL6 IL13 IL10 IFNG
17
Show member pathways
12.41 TNF IL6 IL10 CXCR3 CXCL8
18
Show member pathways
12.41 TNF MPO IL6 IFNG CRP
19
Show member pathways
12.37 TNF MMP9 IL6 IL17A IL13 IFNG
20 12.3 MPO MMP9 IL6 CXCL8
21 12.28 TNF IL6 IL10 IFNG
22
Show member pathways
12.27 TNF SFTPD IL6 IFNG CXCL8
23 12.26 TNF IL6 IL13 IL10 CXCL8
24 12.24 TNF MMP9 IL6 IFNG
25 12.15 TNF PDGFB MMP9 IFNG
26
Show member pathways
12.14 TNF IL6 IL17A IL10 IFNG
27
Show member pathways
12.12 TNF MMP9 IL6 IL13 IFNG
28 12.09 TNF MMP9 IL6 IFNG CXCL8
29 12.08 TNF IL6 IL10 CXCL8
30 12.07 TNF MPO IL6 IL10 IFNG
31 12 TNF IL6 IL10 IFNG CXCL8
32
Show member pathways
11.98 TNF TIMP1 MMP9 MMP8
33
Show member pathways
11.95 IL6 IL17A FOXP3 CXCL8
34 11.94 TNF IL6 IL17A IFNG CXCL8
35 11.89 IL6 IL13 IFNG CXCL8
36
Show member pathways
11.86 TNF TIMP1 PDGFB IL6 IL17A IL13
37 11.85 TNF IL6 IL10 CXCL8
38
Show member pathways
11.85 TNF IFNG FOXP3 CXCL8
39 11.84 TNF IL6 IL10 IFNG
40 11.81 IL6 IFNG CXCL8
41 11.78 TNF IL17A IL13 IL10 IFNG CXCR3
42 11.72 MMP9 IL6 CXCL8
43
Show member pathways
11.72 TNF MMP9 IL6 IFNG CXCL8
44 11.69 TIMP1 MMP9 CXCL8
45 11.66 TNF IL6 CXCL8
46 11.65 TNF MMP9 IL6 IL17A IL13 IL10
47 11.64 IL6 IFNG CXCL8
48 11.62 TNF MPO MMP9 IL6
49 11.61 TNF IL6 IL10 IFNG CXCL8
50 11.6 TNF IL6 IFNG

GO Terms for Bronchiolitis Obliterans

Cellular components related to Bronchiolitis Obliterans according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.86 TNF TIMP1 SFTPD SCGB1A1 PDGFB MPO
2 extracellular space GO:0005615 9.53 TNF TIMP1 SFTPD SCGB1A1 PDGFB MPO

Biological processes related to Bronchiolitis Obliterans according to GeneCards Suite gene sharing:

(show all 44)
# Name GO ID Score Top Affiliating Genes
1 extracellular matrix organization GO:0030198 9.99 TNF PDGFB MMP9 MMP8
2 negative regulation of gene expression GO:0010629 9.99 TNF PDGFB MMP8 IFNG FOXP3
3 cellular response to lipopolysaccharide GO:0071222 9.96 TNF IL6 IL10 CXCL8
4 response to lipopolysaccharide GO:0032496 9.95 SCGB1A1 MPO IL13 IL10
5 immune response GO:0006955 9.91 TNF IL6 IL17A IL13 IL10 IFNG
6 positive regulation of endothelial cell proliferation GO:0001938 9.86 PDGFB IL10 BMP6
7 extracellular matrix disassembly GO:0022617 9.85 TIMP1 MMP9 MMP8
8 response to mechanical stimulus GO:0009612 9.85 PPL MPO IL13
9 positive regulation of interleukin-6 production GO:0032755 9.84 TNF MMP8 IL6
10 humoral immune response GO:0006959 9.84 TNF IL6 IFNG
11 response to organic substance GO:0010033 9.83 TNF TIMP1 SCGB1A1 IL10
12 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.81 TNF IL6 IL13 IFNG
13 positive regulation of phagocytosis GO:0050766 9.8 TNF SFTPD IFNG
14 positive regulation of nitric oxide biosynthetic process GO:0045429 9.8 TNF MMP8 IFNG
15 positive regulation of smooth muscle cell proliferation GO:0048661 9.8 TNF PDGFB IL6 IL13
16 negative regulation of interleukin-6 production GO:0032715 9.79 TNF IL10 FOXP3
17 negative regulation of interferon-gamma production GO:0032689 9.76 SCGB1A1 IL10 FOXP3
18 cytokine-mediated signaling pathway GO:0019221 9.76 TNF TIMP1 MMP9 IL6 IL17A IL13
19 positive regulation of JAK-STAT cascade GO:0046427 9.75 TNF IL6 IL10
20 microglial cell activation GO:0001774 9.74 TNF IL13 IFNG
21 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.73 TNF PDGFB MMP9 IL10
22 response to glucocorticoid GO:0051384 9.72 TNF SCGB1A1 IL6 IL10 BMP6
23 positive regulation of osteoclast differentiation GO:0045672 9.71 TNF IL17A IFNG
24 positive regulation of chemokine biosynthetic process GO:0045080 9.69 TNF IFNG
25 negative regulation of amyloid-beta clearance GO:1900222 9.69 TNF IFNG
26 positive regulation of MHC class II biosynthetic process GO:0045348 9.68 IL10 IFNG
27 endothelial cell apoptotic process GO:0072577 9.68 TNF IL10
28 negative regulation of membrane protein ectodomain proteolysis GO:0051045 9.68 TIMP1 IL10
29 negative regulation of T cell proliferation GO:0042130 9.67 SFTPD SCGB1A1 IL10 FOXP3
30 negative regulation of cytokine secretion involved in immune response GO:0002740 9.65 TNF IL10
31 negative regulation of interleukin-2 biosynthetic process GO:0045085 9.65 SFTPD FOXP3
32 positive regulation of neuroinflammatory response GO:0150078 9.65 TNF MMP8 IL6
33 positive regulation of interleukin-23 production GO:0032747 9.64 IL17A IFNG
34 negative regulation of interleukin-5 production GO:0032714 9.64 SCGB1A1 FOXP3
35 negative regulation of interleukin-4 production GO:0032713 9.63 SCGB1A1 FOXP3
36 regulation of neuroinflammatory response GO:0150077 9.63 MMP9 MMP8 IL6
37 regulation of microglial cell activation GO:1903978 9.62 MMP8 IL6
38 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.61 TNF IFNG
39 positive regulation of gene expression GO:0010628 9.61 TNF PDGFB MMP8 IL6 IL13 IFNG
40 receptor biosynthetic process GO:0032800 9.6 TNF IL10
41 negative regulation of lipid storage GO:0010888 9.58 TNF IL6 CRP
42 positive regulation of vitamin D biosynthetic process GO:0060557 9.56 TNF IFNG
43 positive regulation of nitrogen compound metabolic process GO:0051173 9.55 TNF IFNG
44 inflammatory response GO:0006954 9.28 TNF IL6 IL17A IL13 IL10 CXCR3

Molecular functions related to Bronchiolitis Obliterans according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.35 TIMP1 PDGFB IL6 IL10 BMP6
2 cytokine activity GO:0005125 9.28 TNF TIMP1 IL6 IL17A IL13 IL10

Sources for Bronchiolitis Obliterans

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....